DeepCure
AI-driven Drug Discovery
Startup A Health Tech & Life Sciences United States Est. 2018
Total Raised
$46M
A
Last Round
$40M
2 rounds
Investors
3
3 public
Team
3
11-50 employees
Confidence
90/100
News
3
articles
About
DeepCure developed an AI platform designed to search the enormous chemical space with high accuracy. By combining the power of its deep learning algorithms, cloud computing infrastructure, and proprietary database of 1 trillion chemistries, DeepCure's platform finds drug candidates that deliver improved value to patients. DeepCure's proprietary molecular database, MolDB, is a large medicinal chemistry database that covers over 1 trillion compounds and is expanded on demand to 1 quintillion molecules. These compounds are highly diverse and span most of the chemical space currently accessible to chemists. The trillion compounds cover more than 75% of existing medicinal chemistry compounds, including drugs and current clinical candidates in development, synthesized, or reported by medicinal chemists. In addition, a suite of generative models can expand each selected molecule to a million analogs, expanding the search even further to 1 quintillion (10^18) molecules. MolDB enables the discovery of candidates that don't exist in traditional screening libraries.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
Artificial IntelligenceDeep Learning
Target Customer
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business Model
B2B
Tags
drug-developmentdrug-discoverybiotechnologypharmaceuticalsartificial-intelligencedeep-learning
Funding & Events
Nov 2021
A Round $40M
Morningside Venture Investments (Lead), TLV Partners, Sapir Venture Partners
Aug 2019
Seed $6M
TLV Partners, Sapir Venture Partners
News (3)
Jan 4, 2023 · www.businesswire.com
Biosero and DeepCure Collaborate to Establish Fully Automated, AI-Powered Chemistry Synthesis Platform
Apr 26, 2022 · www.businesswire.com
DeepCure Appoints Dr. Han Lim as Chief Business Officer
Nov 8, 2021 · www.businesswire.com
DeepCure Closes $40M Series A Funding Led by Morningside Ventures
Details
Product Stage
Released
Employees
11-50
Exact Count
32
District
Center District
Founded
2018
Registrar
516567518
Locations
Rehovot, Israel
100 City Hall Plaza, Boston, MA 02108, USA
Links
Website
LinkedIn
Twitter
Careers
Admin
Last Update
Nov 8, 2024
Verified by
Maor Perlov
Missing
markets, not claimed
Team (3)
Kfir Schreiber
Co-founder & CEO
Founder
Ofir Bar
Analytical & Purification scientist
Orly Dorot
Senior Scientist
Internal
Created by
Maor Perlov (maorperlov@gmail.com)
Created
2021-11-08T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)